tretinoin has been researched along with Sjogren-s-Syndrome* in 3 studies
3 other study(ies) available for tretinoin and Sjogren-s-Syndrome
| Article | Year |
|---|---|
Human tolerogenic dendritic cells generated with protein kinase C inhibitor are optimal for functional regulatory T cell induction - A comparative study.
Tolerogenic dendritic cells (tDCs) are a promising therapeutic tool for specific induction of immunological tolerance. Human tDCs can be generated ex vivo using various compounds. However, the compound(s) most suitable for clinical application remain undefined. We compared the tolerogenic properties of tDCs treated with protein kinase C inhibitor (PKCI), dexamethasone, vitamin D3 (Vit D3), rapamycin (Rapa), interleukin (IL)-10, transforming growth factor (TGF)-β, and a combination of peroxisome proliferator-activated receptor γ agonist and retinoic acid. All tDCs had a semi-mature DC phenotype. PKCI-, TGF-β-, and Rapa-tDCs showed CCR7 expression and migration to CCL19, but other tDCs showed little or none. PKCI- and IL-10-tDCs induced functional regulatory T cells more strongly than other tDCs. The tolerogenic properties of all tDCs were stable against proinflammatory stimuli. Furthermore, PKCI-tDCs were generated from patients with rheumatoid arthritis and primary Sjögren's syndrome. Therefore, PKCI-tDCs showed the characteristics best suited for tolerance-inducing therapy. Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Chemotaxis; Cholecalciferol; Cytokines; Dendritic Cells; Dexamethasone; Female; Humans; Immune Tolerance; Male; Middle Aged; Phagocytosis; PPAR gamma; Protein Kinase C; Protein Kinase Inhibitors; Sirolimus; Sjogren's Syndrome; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Tretinoin | 2016 |
Topical tretinoin treatment for dry-eye disorders.
Topics: Administration, Topical; Aged; Conjunctiva; Female; Humans; Metaplasia; Sjogren's Syndrome; Tretinoin | 1987 |
Treatment of the ichthyosis of the Sjögren-Larsson syndrome with etretinate (Tigason).
The ichthyosis of seven patients with the Sjögren-Larsson syndrome was treated with an aromatic retinoid, etretinate, during six months. Very good results were registered in six of the patients measured both as clinical improvement and as reduction in quantity of emollients needed. No unexpected side effects were noted. Topics: Adolescent; Adult; Aged; Etretinate; Humans; Ichthyosis; Middle Aged; Pruritus; Sjogren's Syndrome; Time Factors; Tretinoin | 1983 |